Skip to main content

XORTX Therapeutics Inc. (XRTX)

New York Stock Exchange Healthcare BiotechnologyView data quality →
42.6Fair

ValueMarkers Composite Index

Top 9%#40,864 of 44,714
Undervalued

54% below intrinsic value ($1)

UndervaluedFair ValueOvervalued
Piotroski
0/9
Weak
Beneish
-
Altman
-15.91
Distress
DCF Value
$1
Undervalued
ROIC
-121.0%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

XORTX Therapeutics Inc. (XRTX) — VMCI valuation read

XRTX prints VMCI 43/100 inside the Healthcare sector, where the median sits at 50. The 7-point below-median delta is the cleanest single-number summary of XORTX Therapeutics Inc.'s composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.

On XRTX, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** XRTX trades at 20.0x earnings, 11% above the Healthcare median of 18.0x; that is the value line. ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of -1.2x leaves covenant headroom; that is the risk line for XORTX Therapeutics Inc. on the trailing financials.

XRTX rose 1.5% over the trailing 7 days, with a -22.1% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in XRTX’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.